A Phase 1 Study of RMC-9805 in People With Solid Tumors

Full Title

Purpose

Researchers want to find the best dose of RMC-9805 to use in people with advanced solid tumors. The people in this study have cancer that keeps growing even with treatment. The tumors also have a mutation (change) in the KRAS gene called G12D.

RMC-9805 works against cancer by targeting the mutated KRASG12D protein in cancer cells. This protein plays a role in cancer growth. By blocking it, RMC-9805 may slow or stop the growth of your cancer. RMC-9805 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a solid tumor that keeps growing even with treatment, or you must have been unable to tolerate the treatment.
• Have the KRASG12D mutation.
• Have recovered from the serious side effects of prior anti-cancer therapies.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Eileen O’Reilly’s office at 646-888-4182.